氧化使用与老年风湿性关节炎患者的死亡风险降低有关
Priyanka Iyer1, Yubo Gao2, Diana Jalal3
1Division of Rheumatology, University of California at Irvine, Irvine, CA, USA.
Clinical rheumatology
|July 27, 2023
概括
在类风湿性关节炎 (RA) 患者中使用氧化 (HCQ) 并没有增加主要心血管不良事件 (MACE). 然而,HCQ与该人群全因死亡风险降低有关.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于氧化 (HCQ) 在类风湿性关节炎 (RA) 患者的心血管安全性的数据有限,该群体经常经历心血管并发症.
- 这项研究调查了HCQ使用与RA患者主要不良心血管事件 (MACE) 之间的关联.
研究的目的:
- 在被诊断患有类风湿性关节炎 (RA) 的患者中评估氧化 (HCQ) 的心血管安全性.
- 确定HCQ启动与主要心血管不良事件 (MACE) 风险和老年RA患者全因死亡率之间的关联.
主要方法:
- 研究人员对65岁及以上的医疗保险受益者进行了回顾性队列研究.
- 启动HCQ的患者与使用倾向分数的非用户相匹配. 结果包括MACE (中风,心肌梗塞,心力衰竭),所有原因死亡率以及MACE和死亡率的复合.
- 考克斯的比例危险模型被用来比较HCQ用户和非用户之间的结果.
主要成果:
- 该研究包括2380名HCQ使用者和4633名匹配的非使用者,平均随访时间约为1.65年.
- 氧化 (HCQ) 的使用与重大心血管不良事件 (MACE) 的风险增加无关.
- 使用HCQ与所有原因死亡率的风险降低以及MACE和所有原因死亡率的复合物显著相关.
结论:
- 在老年类类风湿性关节炎 (RA) 患者中,氧化 (HCQ) 的使用与主要心血管不良事件 (MACE) 的发生率增加无关.
- 在这个患者队列中,HCQ的使用独立地与所有原因死亡率的显著降低有关.
- 这些发现表明,在不增加心血管风险的情况下,HCQ对RA患者的潜在生存益处.
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
20
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
20
01:20Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:23Rheumatic Heart Disease I: Introduction
17
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
17
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195